West Nadja sold $162K of TEM

West Nadja sold 3,000 shares of Tempus AI, Inc. (TEM) at $53.90 ($0.16M total) on 2026-08-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · West Nadja
Published Aug 18, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
high confidence
Mentioned
$TEM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details: 3,000 shares at $53.90 on 2026-08-14, with holdings after the sale of 34,981 shares, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may log the insider sale for sentiment monitoring, but the 10b5-1 structure makes it less actionable as a standalone catalyst.

03

What to watch

The article does not provide context on total holdings, prior sale frequency, or whether the sale was tax-related, limiting inference from the transaction size.

Relevance 3/10Novelty 3/10Timing: Filed 2026-08-18, disclosing an insider sale executed 2026-08-14.

Background

The article is an SEC Form 4 insider transaction disclosure for Tempus AI, Inc. (TEM).

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

Tempus AI director West Nadja sold 3,000 shares in an open-market transaction at $53.90 on 2026-08-14 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an SEC Form 4 insider transaction, but it specifies a 10b5-1 pre-arranged plan, which typically reduces interpretive value versus discretionary selling.

Market effects

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or demand changes.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution, so traders may watch for follow-on sales or other insider activity.

Key entities

  • Tempus AI, Inc.

    Company whose director insider sale is disclosed via SEC Form 4.

  • West Nadja

    Director who sold 3,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.